Search: onr:"swepub:oai:DiVA.org:uu-485917" > Anal cancer in Swed...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04328naa a2200445 4500 | |
001 | oai:DiVA.org:uu-485917 | |
003 | SwePub | |
008 | 221017s2022 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4859172 URI |
024 | 7 | a https://doi.org/10.1080/0284186X.2022.20480692 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Johnsson, Andersu Skane Univ Hosp, Dept Oncol, S-22185 Lund, Sweden.4 aut |
245 | 1 0 | a Anal cancer in Sweden 2015-2019. Implementation of guidelines, structural changes, national registry and early results |
264 | 1 | b Taylor & Francis Group,c 2022 |
338 | a print2 rdacarrier | |
520 | a Background Squamous cell cancer of the anus is an uncommon malignancy, usually caused by human papilloma virus (HPV). Chemoradiotherapy (CRT) is the recommended treatment in localized disease with cure rates of 60-80%. Local failures should be considered for salvage surgery. With the purpose of improving and equalizing the anal cancer care in Sweden, a number of actions were taken between 2015 and 2017. The aim of this study was to describe the implementation of guidelines and organizational changes and to present early results from the first 5 years of the Swedish anal cancer registry (SACR). Methods The following were implemented: (1) the first national care program with treatment guidelines, (2) standardized care process, (3) centralization of CRT to four centers and salvage surgery to two centers, (4) weekly national multidisciplinary team meetings where all new cases are discussed, (5) the Swedish anal cancer registry (SACR) was started in 2015. Results The SACR included 912 patients with a diagnosis of anal cancer from 2015 to 2019, reaching a national coverage of 95%. We could show that guidelines issued in 2017 regarding staging procedures and radiotherapy dose modifications were rapidly implemented. At baseline 52% of patients had lymph node metastases and 9% had distant metastases. Out of all patients in the SACR 89% were treated with curative intent, most of them with CRT, after which 92% achieved a local complete remission and the estimated overall 3-year survival was 85%. Conclusions This is the first report from the SACR, demonstrating rapid nation-wide implementation of guidelines and apparently good treatment outcome in patients with anal cancer in Sweden. The SACR will hopefully be a valuable source for future research. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a Anal cancer | |
653 | a guidelines | |
653 | a chemoradiotherapy | |
700 | 1 | a Norman, Davidu Reg Canc Ctr North, Umeå, Sweden.4 aut |
700 | 1 | a Angenete, Evau Univ Gothenburg, Sahlgrenska Acad, Sahlgrenska Univ Hosp, Dept Surg, Gothenburg, Sweden.;Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Gothenburg, Sweden.4 aut |
700 | 1 | a Cavalli-Björkman, Nina,d 1970-u Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)ninca468 |
700 | 1 | a Lagerbäck, Ceciliau Soder Sjukhuset, Dept Oncol, Stockholm, Sweden.4 aut |
700 | 1 | a Leon, Otiliau Skane Univ Hosp, Dept Oncol, S-22185 Lund, Sweden.4 aut |
700 | 1 | a Lindh, Birgittau Univ Hosp Northern Sweden, Dept Oncol, Umeå, Sweden.4 aut |
700 | 1 | a Lydrup, Marie-Louiseu Skane Univ Hosp, Dept Surg, Malmö, Sweden.4 aut |
700 | 1 | a Nilsson, Martin P.u Skane Univ Hosp, Dept Oncol, S-22185 Lund, Sweden.4 aut |
700 | 1 | a Perman, Matsu Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden.4 aut |
700 | 1 | a Radu, Calin,d 1969-u Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)calra471 |
700 | 1 | a Zackrisson, Björnu Univ Hosp Northern Sweden, Dept Oncol, Umeå, Sweden.4 aut |
710 | 2 | a Skane Univ Hosp, Dept Oncol, S-22185 Lund, Sweden.b Reg Canc Ctr North, Umeå, Sweden.4 org |
773 | 0 | t Acta Oncologicad : Taylor & Francis Groupg 61:5, s. 575-582q 61:5<575-582x 0284-186Xx 1651-226X |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-485917 |
856 | 4 8 | u https://doi.org/10.1080/0284186X.2022.2048069 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.